PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 4013832

Digoxin-trimethoprim interaction.

P Petersen·J Kastrup·R Bartram·J Mølholm Hansen
View original source ↗Export metadata ↓

Abstract

Nine patients (median age 78 years, range 62-92) treated with a constant oral dosage of digoxin were evaluated for the effect of trimethoprim on serum digoxin values. Serum digoxin increased by 22% during trimethoprim treatment (p less than 0.05). Subsequently, 6 healthy subjects (median age 29 years, range 24-31) were evaluated for the effect of trimethoprim on digoxin pharmacokinetics after an i.v. dose. Trimethoprim administration did not affect total body clearance of digoxin and the glomerular filtration rate. The renal clearance of digoxin decreased by 17% (p less than 0.05) and the extrarenal clearance of digoxin increased by 14% (N.S.). Biological half-life of digoxin and apparent volumes of central and peripheral compartments were unchanged during the study. It is suggested that the increase in serum digoxin in the elderly patients is due to decreased renal tubular secretion of digoxin and not to disturbance of the extrarenal clearance.

Explore related subjects

Administration, OralAdultAgedDigoxinDose-Response Relationship, DrugFemaleHalf-LifeHumansInfusions, ParenteralKineticsMaleMiddle AgedTrimethoprimComparative StudyJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Petersen, J Kastrup, R Bartram, J Mølholm Hansen. 1985. Digoxin-trimethoprim interaction.. https://doi.org/10.1111/j.0954-6820.1985.tb02718.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Evaluation of early embryonic loss induced by tributyltin chloride in rats: phase- and dose-dependent antifertility effects.

In our previous study, tributyltin chloride (TBTCl) on days 0-7 of pregnancy was found to produce implantation failure in rats. The objective of the present study was to determine the susceptible period for the antifertility effect of TBTCl in rats. Inseminated females were orally administered TBTCl at 8.1, 16.3, or 32.5 mg/kg on days 0-3 of pregnancy, or at 8.1, 16.3, 32.5, or 65.1 mg/kg on days 4-7 of pregnancy. Pregnancy outcome was determined on day 20 of pregnancy. Dosing with TBTCl on days 0-3 of pregnancy at 16.3 mg/kg and higher produced a significant increase in the rate of implantation failure. Dosing with TBTCl on days 4-7 of pregnancy caused a significant increase in the incidence of postimplantation loss at 16.3 mg/kg and higher in females with implantations. No increase in the incidence of fetal malformations was found in any TBTCl-treated groups. It could be concluded that the susceptibility to and manifestation of the antifertility effects of TBTCl vary with the gestational stage at the time of administration.

Administration, Oral↗
PubMed1998

Antibody-secreting cell responses and protective immunity assessed in gnotobiotic pigs inoculated orally or intramuscularly with inactivated human rotavirus.

Newborn gnotobiotic pigs were inoculated twice perorally (p.o.) (group 1) or intramuscularly (i.m.) (group 2) or three times i.m. (group 3) with inactivated Wa strain human rotavirus and challenged with virulent Wa human rotavirus 20 to 24 days later. To assess correlates of protection, antibody-secreting cells (ASC) were enumerated in intestinal and systemic lymphoid tissues from pigs in each group at selected postinoculation days (PID) or postchallenge days. Few virus-specific ASC were detected in any tissues of group 1 pigs prior to challenge. By comparison, groups 2 and 3 had significantly greater numbers of virus-specific immunoglobulin M (IgM) ASC in intestinal and splenic tissues at PID 8 and significantly greater numbers of virus-specific IgG ASC and IgG memory B cells in spleen and blood at challenge. However, as for group 1, few virus-specific IgA ASC or IgA memory B cells were detected in any tissues of group 2 and 3 pigs. Neither p.o. nor i.m. inoculation conferred significant protection against virulent Wa rotavirus challenge (0 to 6% protection rate), and all groups showed significant anamnestic virus-specific IgG and IgA ASC responses. Hence, high numbers of IgG ASC or memory IgG ASC in the systemic lymphoid tissues at the time of challenge did not correlate with protection. Further, our findings suggest that inactivated Wa human rotavirus administered either p.o. or parenterally is significantly less effective in inducing intestinal IgA ASC responses and conferring protective immunity than live Wa human rotavirus inoculated orally, as reported earlier (L. Yuan, L. A. Ward, B. I. Rosen, T. L. To, and L. J. Saif, J. Virol. 70:3075-3083, 1996). Thus, more efficient mucosal delivery systems and rotavirus vaccination strategies are needed to induce intestinal IgA ASC responses, identified previously as a correlate of protective immunity to rotavirus.

Administration, Oral↗